Studies salt intake and disease activity in spondyloarthritis and psoriatic arthritis
Looks at how dietary salt relates to disease activity in adults with joint inflammation.
Plain-language title generated from the registry record
Registry title: Influence of Sodium Intake in spondyLoarthriTes
Key facts
- Where
- Besançon, La Roche-sur-Yon, Saint-Etienne, and Trévenans, FranceSee the 4 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT06259890, who can take part
Where in France
- CHU BesançonBesançon, FranceTaking people
- CHD VendéeLa Roche-sur-Yon, FranceTaking people
- Chu St-EtienneSaint-Etienne, FranceTaking people
- Hôpital Nord Franche-ComtéTrévenans, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Centre Hospitalier Universitaire de Besancon
- Trial code
- NCT06259890
- Record updated
- 9 July 2025
- Original description
The aim of the SALT study is to analyze the relationship between dietary sodium intake and disease activity in patients with axial spondyloarthritis (radiographic or non-radiographic) or psoriatic arthritis.Read full original descriptionShow less
Sodium Intake in spondyLoarthriTes: Analysis of the Influence on the Activity of the Disease and the Therapeutic Response to Anti IL-17A Agents.
The aim of the SALT study is to analyze the relationship between dietary sodium intake and disease activity in patients with axial spondyloarthritis (radiographic or non-radiographic) or psoriatic arthritis.
Inclusion: patients with axial spondyloarthritis (radiographic or non-radiographic) or psoriatic arthritis; women who have been menopausal for at least 24 months, surgically sterilized, or, for women of childbearing potentiale, use an effective method of contraception (oral contraceptives, contraceptive injections, intrauterine devices, double-barrier method, contraceptive patches).
Exclusion: patient treated by cyclosporine, diuretics, angiotensin-converting enzyme inhibitors or angiotensin II receptor antagonists; current treatment with an anti-IL-17A agent (secukinumab or ixekizumab or bimekizumab or brodalumab) or with an anti-IL23 agent (ustekinumab, guselkumab, risankizumab or tildrakizumab) or previous treatment less than 6 months old; patients on systemic corticosteroids with corticosteroid therapy > 10 mg prednisone equivalent; pregnant woman.